GlassScriptPhysician profile
Dawei Zheng
NPI 1912973520
$14,810.72
in general payments reported to CMS, 2019-2025
56 companies · $1,526 in 2025
The $1,526 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,919 · 2020: $2,252 · 2021: $2,594 · 2022: $2,463 · 2023: $2,462 · 2024: $1,595 · 2025: $1,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,483 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,482.66 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,863.21 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $1,609.27 | 2019-2024 | Xarelto, Spravato |
| Gilead Sciences, INC. | $1,225.06 | 2019-2025 | |
| Lilly USA, LLC | $856.29 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $725.23 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $646.86 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $645.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $617.05 | 2022-2025 | |
| Abbvie INC. | $577.66 | 2019-2024 | Linzess, Viberzi, Creon |
| Merck Sharp & Dohme LLC | $559.36 | 2019-2025 | Verquvo, Capvaxive, Belsomra |
| Amgen INC. | $549.13 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Amarin Pharma, INC. | $535.81 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $437.12 | 2019-2025 | Linzess |
| Pfizer INC. | $433.32 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $372.85 | 2019-2023 | Relistor |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawei Zheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.